Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012389 · ClinicalTrials.gov registry record · Phase 3
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00012389 is a Phase 3 study that has completed, run by Sanofi.
The verdict
NCT00012389, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of irinotecan with or without oxaliplatin in treating patients who have metastatic colorectal cancer.
Interventions
- DRUG oxaliplatin
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-12 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012389
The ClinicalTrials.gov registry entry for NCT00012389 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00012389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012389 about?
NCT00012389 is a clinical study titled "Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic colorectal cancer. PURPOSE: Randomized phase III trial to compare the effect...
What is the current status of trial NCT00012389?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-12. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00012389?
The interventions under investigation include: oxaliplatin (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00012389?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.